Skip to content

A clinical study on the feasibility and safety of single-port inflatable mediastinoscopycombined with sing-port laparoscopic esophagectomy for esophageal carcinoma

A clinical study on the feasibility and safety of radical resection of single-port inflatable mediastinoscopy combined with sing-port laparoscopic esophagectomy for esophageal carcinoma

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043728
Enrollment
Unknown
Registered
2021-02-27
Start date
2021-02-22
Completion date
Unknown
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

single arm:single-port inflatable mediastinoscopy combined with sing-port laparoscopic esophagectomy

Sponsors

The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
23 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Subjects older than or equal to 23 years old; 2. Patients with esophageal squamous cell carcinoma confirmed by cytology or histology and solid tumors requiring surgical treatment; 3. Patients with t1-2n0-1m0 stage confirmed by ultrasonic gastroscopy before operation; Or patients with T3N1M0 (IIIA) stage, old age, right lung surgery history, and feasible surgical resection; 4. Patients with tumor located in thoracic or abdominal esophagus; 5. Patients whose tumor did not invade surrounding important organs and pet CT showed no distant metastasis; 6. Patients in good general condition, without serious complications, can tolerate general anesthesia; 7. Patients who voluntarily signed informed consent before the study.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors at the same time; 2. Patients with previous history of esophagectomy or gastrectomy; 3. Patients with previous mediastinal surgery or extensive abdominal adhesions; 4. Patients with distant metastasis confirmed by pathology or highly suspected clinically are not suitable for operation; 5. Subjects with other comorbid diseases (such as obvious abnormality of liver and kidney function) or combined medication, which may affect the results of this study according to the judgment of the researchers.

Design outcomes

Primary

MeasureTime frame
operative time;postoperative complications;The number of dissected lymph node;

Secondary

MeasureTime frame
postoperative pain score;intraoperative blood loss;

Countries

China

Contacts

Public ContactXu Li

Department of Thoracic Surgery, the First Affiliated Hospital of Fujian Medical University

lixu1967@hotmail.com+86 13705011308

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026